The present invention relates generally to obturators for peripheral IV catheters or other vascular access devices. In particular, the present invention relates to obturators that are configured to provide antimicrobial protection to vascular access devices when the obturators are inserted within the vascular access devices.
Catheters are commonly used for a variety of infusion therapies. For example, catheters are used for infusing fluids, such as normal saline solution, various medicaments, and total parenteral nutrition into a patient, withdrawing blood from a patient, as well as monitoring various parameters of the patient's vascular system.
Catheter-related bloodstream infections are caused by the colonization of microorganisms in patients with intravascular catheters and I.V. access devices. These infections are an important cause of illness and excess medical costs. More importantly, these infections often result in patient deaths.
Many techniques have been employed to reduce the risk of infection from a catheter or other intravenous device. For example, catheters have been designed that employ an antimicrobial lubricant or an antimicrobial coating on an inner or outer surface of the catheter. Similarly, antimicrobial lubricants or coatings have been applied to the surfaces of other components of a catheter assembly, components attached to the catheter assembly, or other medical devices which may come in direct contact with the patient's vasculature or in contact with a fluid that may enter the patient's vasculature. Further, some devices or components are made of a material that is impregnated with an antimicrobial agent.
Although these techniques have been beneficial, there are various drawbacks that limit their usefulness. For example, it can be difficult and/or expensive to apply an antimicrobial coating or lubricant to the complex internal and external geometries of many devices or components. Also, some devices or components are preferably made of a material that is not suitable for the application of an antimicrobial coating or that cannot be impregnated with an antimicrobial agent. Because of such difficulties, the current techniques for providing antimicrobial protection are oftentimes not used or, if used, are not adequately applied to provide maximum antimicrobial protection.
The present invention extends to obturators for vascular access devices. An obturator configured in accordance with the present invention can include antimicrobial features which assist in sterilizing or maintaining the sterility of fluid contained within a vascular access device while the device is not being used for infusion or other access to the patient's vasculature.
These antimicrobial features include antimicrobial coatings applied to various surfaces of an obturator and antimicrobial components bonded or otherwise secured to an obturator. Various combinations of antimicrobial coatings and/or components can be used on an obturator as necessary to provide a desired amount of antimicrobial agents within a particular enclosed volume of a vascular access device.
In one embodiment, the present invention is implemented as an obturator for a vascular access device. The obturator includes a catheter portion configured to be inserted through a lumen of the vascular access device and into a proximal end of a catheter of the vascular access device while the catheter is placed intravenously within a patient, and a cap portion configured to secure the obturator to the vascular access device. The catheter portion includes an antimicrobial coating configured to release an antimicrobial agent into fluid contained within the vascular access device.
In another embodiment, the present invention is implemented as an obturator for a vascular access device. The obturator includes a catheter portion configured to be inserted through a lumen of the vascular access device and into a proximal end of a catheter of the vascular access device while the catheter is placed intravenously within a patient, a middle portion configured to be positioned within the lumen of the vascular access device while the catheter portion is inserted into the catheter, and a cap portion configured to secure the obturator to the vascular access device. The obturator further includes an antimicrobial ring positioned around the middle portion. The antimicrobial ring is configured to release an antimicrobial agent into fluid contained within the lumen of the vascular access device.
In another embodiment, the present invention is implemented as an obturator for a vascular access device. The obturator includes a catheter portion configured to be inserted through a lumen of the vascular access device and into a proximal end of a catheter of the vascular access device while the catheter is placed intravenously within a patient, and a base portion configured to be inserted into the lumen to seal the lumen. The obturator further includes an antimicrobial component that is configured to release an antimicrobial agent into fluid contained within the lumen of the vascular access device.
This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key features or essential features of the claimed subject matter.
Additional features and advantages of the invention will be set forth in the description which follows, and in part will be obvious from the description, or may be learned by the practice of the invention. The features and advantages of the invention may be realized and obtained by means of the instruments and combinations particularly pointed out in the appended claims. These and other features of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.
In order to describe the manner in which the above-recited and other advantages and features of the invention can be obtained, a more particular description of the invention briefly described above will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. Understanding that these drawings depict only typical embodiments of the invention and are not therefore to be considered to be limiting of its scope, the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:
The present invention extends to obturators for vascular access devices. An obturator configured in accordance with the present invention can include antimicrobial features which assist in sterilizing or maintaining the sterility of fluid contained within a vascular access device while the device is not being used for infusion or other access to the patient's vasculature.
These antimicrobial features include antimicrobial coatings applied to various surfaces of an obturator and antimicrobial components bonded or otherwise secured to an obturator. Various combinations of antimicrobial coatings and/or components can be used on an obturator as necessary to provide a desired amount of antimicrobial agents within a particular enclosed volume of a vascular access device.
In one embodiment, the present invention is implemented as an obturator for a vascular access device. The obturator includes a catheter portion configured to be inserted through a lumen of the vascular access device and into a proximal end of a catheter of the vascular access device while the catheter is placed intravenously within a patient, and a cap portion configured to secure the obturator to the vascular access device. The catheter portion includes an antimicrobial coating configured to release an antimicrobial agent into fluid contained within the vascular access device.
In another embodiment, the present invention is implemented as an obturator for a vascular access device. The obturator includes a catheter portion configured to be inserted through a lumen of the vascular access device and into a proximal end of a catheter of the vascular access device while the catheter is placed intravenously within a patient, a middle portion configured to be positioned within the lumen of the vascular access device while the catheter portion is inserted into the catheter, and a cap portion configured to secure the obturator to the vascular access device. The obturator further includes an antimicrobial ring positioned around the middle portion. The antimicrobial ring is configured to release an antimicrobial agent into fluid contained within the lumen of the vascular access device.
In another embodiment, the present invention is implemented as an obturator for a vascular access device. The obturator includes a catheter portion configured to be inserted through a lumen of the vascular access device and into a proximal end of a catheter of the vascular access device while the catheter is placed intravenously within a patient, and a base portion configured to be inserted into the lumen to seal the lumen. The obturator further includes an antimicrobial component that is configured to release an antimicrobial agent into fluid contained within the lumen of the vascular access device.
An obturator for a vascular access device is commonly used as a means of sealing the lumen of a catheter of a vascular access device while the catheter is positioned intravenously but is not being used for infusion, medication administration, or other types of vascular access. As an example, an obturator may be inserted within a peripheral intravenous catheter when the peripheral intravenous catheter will not be used to access the patient's vasculature for a substantial amount of time (e.g. 24 hours).
Obturator 100 includes a catheter portion 101, a middle portion 102, a base portion 103, and a cap portion 104. Catheter portion 101 is sized so that is can be inserted within the catheter of a peripheral intravenous catheter. In many cases, the outer diameter of catheter portion 101 is configured to be substantially the same as the inner diameter of the catheter of a peripheral intravenous catheter in which obturator 100 is to be used so that catheter portion 101 forms a seal preventing the flow of fluids through the catheter. Accordingly, catheter portion 101 can be defined as the portion of the obturator that is configured to be inserted into a catheter of a vascular access device.
Catheter portion 101 can be configured with various lengths. For example, the length of catheter portion 101 can be configured so that the distal end of catheter portion 101 is positioned at or near the distal end of the catheter. Alternatively, the length of catheter portion 101 can be configured so that the distal end of catheter portion 101 extends distally out from the catheter. Similarly, the length of catheter portion 101 can be configured so that the distal end of the catheter portion is positioned proximally to the distal end of the catheter. In short, the specific length of catheter portion 101 is not essential to the invention and any length of catheter portion 101 can be employed as long as catheter portion 101 extends at least partially into the catheter when obturator 100 is inserted into the vascular access device.
Middle portion 102 comprises a length of obturator 100 that is positioned between catheter portion 101 and base portion 103. In
Base portion 103 comprises a portion of obturator 100 having a diameter that is substantially the same as the diameter of the lumen of the vascular access device in which the obturator is used. Therefore, a purpose of base portion 103 is to seal the lumen of a vascular access device. Although the figures illustrate obturators that include base portions configured to seal the lumen of a vascular access device, an obturator in accordance with the present invention does not require a base portion configured in this manner. For example, an obturator can include a base portion that has a diameter that is less than the diameter of the lumen such that the base portion does not seal the lumen.
Cap portion 104 comprises a proximal portion of obturator 100 that is configured to secure the obturator to the vascular access device. In some embodiments such as is shown in the figures, cap portion 104 can be configured to extend overtop the proximal end of the vascular access device. In such embodiments, an inner surface of cap portion 104 can include threads for locking the cap portion 104 to the vascular access device. Alternatively, an inner surface of cap portion 104 can be configured to form a friction fit with the outer surface of the vascular access device. In other embodiments, cap portion 104 can be designed so that no portion extends overtop the exterior of the vascular access device. In essence, a cap portion 104 can be defined as the portion of the obturator that the user grips to insert and remove the obturator from a vascular access device. In many cases, cap portion 104 will also form a cover overtop the proximal opening of the vascular access device, but this is not required by the invention.
Although this description describes an obturator as including distinct catheter, middle, base, and cap portions, the intent of this description is to assist in the understanding of the invention and should not be construed as limiting the claims. In particular, an obturator in accordance with the present invention could be configured only with distinct cap and catheter portions with the cap portion being the portion that a user grips and the catheter portion extending distally from the cap portion.
In accordance with one or more embodiments of the invention, obturator 100 can also include an antimicrobial coating on one or more portions. The location of the antimicrobial coating can be selected so that the antimicrobial coating will be in contact with residual fluid that remains within the vascular access device after use. As this residual fluid contacts the antimicrobial coating, one or more antimicrobial agents contained within the coating can be dispersed (e.g. eluted or dissolved) into the residual fluid thereby sterilizing or maintaining the sterility of the fluid. In this way, the risk of microbial colonization within the vascular access device is reduced.
As depicted in
As shown in
In the example shown in
Obturator 200, like obturator 100, includes a catheter portion 201, a middle portion 202, a base portion 203, and a cap portion 204. In some embodiments, obturator 200 may also include antimicrobial coating 110, as described above, on catheter portion 201. However, in describing
In accordance with one or more embodiments of the invention, obturator 200 can also include an antimicrobial ring 210. Antimicrobial ring 210 can comprise a material that contains one or more antimicrobial agents. As will be further described below, the antimicrobial agents can be contained within the material or on the surface (e.g. as a coating) of the material from which the ring is made. The location of antimicrobial ring 210 can be selected so that the antimicrobial ring will be in contact with residual fluid that remains within the vascular access device after use. As this residual fluid contacts the antimicrobial ring, one or more antimicrobial agents contained within the ring can be dispersed (e.g. eluted or dissolved) into the residual fluid thereby sterilizing or maintaining the sterility of the fluid. In this way, the risk of microbial colonization within the vascular access device is reduced.
As shown in
As stated above, in some embodiments, antimicrobial ring 210 can be used on an obturator that also includes an antimicrobial coating 110 on its catheter portion. Using both can ensure that adequate amounts of antimicrobial agents are dispensed in both the catheter and lumen of the catheter adapter since antimicrobial ring 210 can account for the increased amount of antimicrobial agents required to effectively treat the larger volume of the lumen.
In addition to a ring, antimicrobial components of other shapes can also be employed. For example, many differently shaped antimicrobial components can be affixed to an obturator at various locations to provide antimicrobial benefits to a vascular access device. Accordingly, an obturator in accordance with the present invention may include one or more antimicrobial components that are affixed or otherwise secured to the obturator.
Various types of antimicrobial coatings can be employed on obturators in accordance with embodiments of the present invention. In some embodiments, an alcohol-based formulation containing one or more antimicrobial agents can be applied to the surface (e.g. catheter portion 101) of the obturator such as by dipping or spraying. Once applied, the alcohol can dissolve from the surface leaving behind a residue containing the antimicrobial agents thereby forming the antimicrobial coating. In such embodiments, the antimicrobial coating thus formed will dissolve into the fluid within the vascular access device. Using a dissolvable antimicrobial coating can be preferred in many applications where an obturator will be used over a relatively shorter duration of time since the rapid dissolving of the coating results in a quick release of the antimicrobial agents into the fluid. Examples of suitable formulations and methods that can be used to apply the formulations on an obturator are disclosed in U.S. patent application Ser. No. 13/438,559, titled Systems and Methods for Applying a Novel Antimicrobial Coating Material to a Medical Device which is incorporated by reference.
In other embodiments, an antimicrobial coating can be formed of a matrix that includes one or more antimicrobial agents. For example, the matrix can be a polymer or other suitable material that is cured (e.g. via UV curing) or otherwise bonded to the surface of the obturator. In such coatings, the antimicrobial agent will be eluted from the matrix coating in a controlled fashion. Examples of suitable matrixes and methods of applying the matrixes that can be employed to form an antimicrobial coating on an obturator are described in U.S. Pat. No. 8,512,294, titled Vascular Access Device Antimicrobial Materials and Solutions; and U.S. patent application Ser. No. 12/397,760, titled Antimicrobial Compositions; Ser. No. 12/476,997, titled Antimicrobial Coating Compositions; Ser. No. 12/490,235, titled Systems and Methods for Applying an Antimicrobial Coating to a Medical Device; and Ser. No. 12/831,880, titled Antimicrobial Coating for Dermally Invasive Devices; each of which is incorporated by reference.
In some embodiments, an antimicrobial component (e.g. a ring) can be formed of any suitable material and can have an antimicrobial coating formed of either an alcohol-based formulation or a base material matrix and antimicrobial agents as described in the previous paragraphs. In other embodiments, the material from which the antimicrobial component is made can comprise the base material matrix and the antimicrobial agents. In other words, an antimicrobial component can be comprised entirely of a base material matrix or can only have a coating comprised of either the base material matrix or the alcohol-based formulation. In either case, an antimicrobial component can be bonded or mechanically connected to an obturator.
In embodiments of the invention, an obturator can be configured with one or more of the three general types of antimicrobial protection described above. In other words, an obturator can include an antimicrobial coating formed using an alcohol-based formulation, an antimicrobial coating formed of a base material matrix, and an antimicrobial component (whether formed entirely of a base material matrix, having only a coating of a base material matrix, or having a coating of an alcohol-based formulation). Various combinations of these types of antimicrobial protection can be employed on an obturator to give the obturator the desired antimicrobial properties when used within a vascular access device.
In many obturator designs, the catheter portion and base portion of the obturator form seals at opposite ends of the vascular access device effectively creating a locked volume of fluid within the vascular access device. Based on a typical volume of fluid that can be expected to exist within a vascular access device, an obturator can be configured with an appropriate antimicrobial coating and/or component to ensure that the typical volume of fluid will be adequately treated.
To provide an appropriate amount of antimicrobial agents, various factors can be considered including the total surface area or amount (e.g. in weight) of the antimicrobial coating on the obturator, the concentration of the antimicrobial agents within the coating or material, the rate at which the coating or material will elute or dispense the antimicrobial agents, and the type of antimicrobial agent. For example, to achieve a typical inhibitory concentration of 20 ppm for Pseudomonas aeruginosa in a locked volume of 0.16 cc of fluid within a catheter adapter over a 24 hour period, 3.2 μg of chlorhexidine would need to be released from the obturator. Additionally, to attain a typical bacteriocidal concentration of 500 ppm for Pseudomonas aeruginosa, a minimum of 80 μg of chlorhexidine would need to be released from the obturator. Accordingly, in an embodiment where the obturator includes an antimicrobial coating formed using an alcohol-based formulation (i.e. a coating from which the agents dissolve) and the obturator is desired to provide protection against Pseudomonas aeruginosa, an antimicrobial coating having a minimum target weight may range from 3.5 to 81 μg (depending on whether an inhibitory or bacteriocidal concentration is desired). On the other hand, in an embodiment where the obturator includes an antimicrobial coating or component comprised of a base material matrix containing antimicrobial agents (i.e. a coating or component that elutes the agents) and it is desired that the obturator provide antimicrobial protection for a 24 hour period, an antimicrobial coating or component having a surface area as small as 2.5 mm2 may be suitable.
The above examples illustrate that the specific weight of a dissolving antimicrobial coating or surface area of an eluting antimicrobial coating/component can be selected based on the targeted microorganism, the desired antimicrobial effect (e.g. inhibitory or bacteriocidal concentration), the desired duration for which the antimicrobial agents will be effective, the release kinetics (e.g. rate of dissolution or elution) of the coating/component, and the type of antimicrobial agent used (e.g. chlorhexidine gluconate and chlorhexidine diacetate).
One benefit of employing an obturator to distribute antimicrobial agents within a vascular access device between uses of the device is that the obturator can be modified to include an antimicrobial coating and/or component without modifying how the obturator is used. The obturator is therefore a simple means for placing antimicrobial agents in the precise location within the device and at the precise time when they are needed. Another benefit is that an obturator can be provided with an antimicrobial coating and/or component that is configured to distribute a precise amount of antimicrobial agent to the internal volume of the device. As described above, the coating and/or component can be customized based on various factors to provide the necessary amount of antimicrobial agents for a given volume and for a desired purpose.
The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
This application is a continuation of U.S. application Ser. No. 14/260,071, filed Apr. 23, 2014, titled ANTIMICROBIAL OBTURATOR FOR USE WITH VASCULAR ACCESS DEVICES, which is incorporated herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
1844023 | Terry | Feb 1932 | A |
3223629 | Loeffler | Dec 1965 | A |
3598127 | Wepsic | Aug 1971 | A |
3695921 | Shepherd | Oct 1972 | A |
3867937 | Schwartz | Feb 1975 | A |
3986508 | Barrington | Oct 1976 | A |
4068660 | Beck | Jan 1978 | A |
4170996 | Wu | Oct 1979 | A |
4280500 | Ono | Jul 1981 | A |
4334551 | Pfister | Jun 1982 | A |
4339336 | Hammond | Jul 1982 | A |
4387879 | Tauschinski | Jun 1983 | A |
4449693 | Gereg | May 1984 | A |
4469483 | Becker | Sep 1984 | A |
4512766 | Vailancourt | Apr 1985 | A |
4584192 | Dell | Apr 1986 | A |
4585435 | Vaillancourt | Apr 1986 | A |
4592920 | Murtfeldt | Jun 1986 | A |
4603152 | Laurin | Jul 1986 | A |
4610674 | Suzuki | Sep 1986 | A |
4629743 | Hong | Dec 1986 | A |
4629746 | Michl | Dec 1986 | A |
4642126 | Zador | Feb 1987 | A |
4676782 | Yamamoto | Jun 1987 | A |
4677143 | Laurin | Jun 1987 | A |
4716032 | Westfall | Dec 1987 | A |
4723948 | Clark | Feb 1988 | A |
4758225 | Cox | Jul 1988 | A |
4781703 | Walker | Nov 1988 | A |
4798594 | Hillstead | Jan 1989 | A |
4805933 | Swisher | Feb 1989 | A |
4838873 | Landskron | Jun 1989 | A |
4842591 | Luther | Jun 1989 | A |
4846812 | Walker | Jul 1989 | A |
4874377 | Newgard | Oct 1989 | A |
4880414 | Whipple | Nov 1989 | A |
4895566 | Lee | Jan 1990 | A |
4897427 | Barnavon | Jan 1990 | A |
4915934 | Tomlinson | Apr 1990 | A |
4917668 | Haindl | Apr 1990 | A |
4925668 | Khan | May 1990 | A |
4933178 | Capelli | Jun 1990 | A |
4935010 | Cox | Jun 1990 | A |
4950257 | Hibbs | Aug 1990 | A |
4955890 | Yamamoto | Sep 1990 | A |
4976697 | Walder et al. | Dec 1990 | A |
4985399 | Matsuda | Jan 1991 | A |
4990357 | Karakelle | Feb 1991 | A |
5019096 | Fox, Jr. | May 1991 | A |
5023082 | Friedman | Jun 1991 | A |
5030665 | Lee | Jul 1991 | A |
5041097 | Johnson | Aug 1991 | A |
5053014 | Van Heugten | Oct 1991 | A |
5062836 | Wendell | Nov 1991 | A |
5064416 | Newgard | Nov 1991 | A |
5077352 | Elton | Dec 1991 | A |
5078703 | Bryant | Jan 1992 | A |
5084023 | Lemieux | Jan 1992 | A |
5085645 | Purdy | Feb 1992 | A |
5098410 | Kerby | Mar 1992 | A |
5108374 | Lemieux | Apr 1992 | A |
5127905 | Lemieux | Jul 1992 | A |
5129887 | Euteneuer et al. | Jul 1992 | A |
5154703 | Bonaldo | Oct 1992 | A |
5156596 | Balbierz | Oct 1992 | A |
5167647 | Wijkamp | Dec 1992 | A |
5217493 | Raad | Jun 1993 | A |
5226898 | Gross | Jul 1993 | A |
5234410 | Graham | Aug 1993 | A |
5242425 | White | Sep 1993 | A |
5256145 | Atkinson | Oct 1993 | A |
5290246 | Yamamoto | Mar 1994 | A |
5295969 | Fischell | Mar 1994 | A |
5330435 | Vaillancourt | Jul 1994 | A |
5330449 | Prichard | Jul 1994 | A |
5350363 | Goode | Sep 1994 | A |
5352205 | Dales | Oct 1994 | A |
5357636 | Dresdner, Jr. | Oct 1994 | A |
5366505 | Farber | Nov 1994 | A |
5380301 | Prichard | Jan 1995 | A |
5405323 | Rogers | Apr 1995 | A |
5405338 | Kranys | Apr 1995 | A |
5456675 | Wolbring | Oct 1995 | A |
5456948 | Mathisen | Oct 1995 | A |
5487728 | Vaillancourt | Jan 1996 | A |
5512199 | Khan | Apr 1996 | A |
5520666 | Choudhury | May 1996 | A |
5536258 | Folden | Jul 1996 | A |
5540661 | Tomisaka | Jul 1996 | A |
5547662 | Khan | Aug 1996 | A |
5549566 | Elias | Aug 1996 | A |
5549577 | Siegel | Aug 1996 | A |
5575769 | Vaillancourt | Nov 1996 | A |
5589120 | Khan et al. | Dec 1996 | A |
5613663 | Schmidt | Mar 1997 | A |
5616338 | Fox, Jr. | Apr 1997 | A |
5620434 | Brony | Apr 1997 | A |
5629006 | Hoang | May 1997 | A |
5638812 | Turner | Jun 1997 | A |
5651772 | Arnett | Jul 1997 | A |
5653695 | Hopkins | Aug 1997 | A |
5657963 | Hinchliffe | Aug 1997 | A |
5658253 | Piontek | Aug 1997 | A |
5676656 | Brimhall | Oct 1997 | A |
5688747 | Khan | Nov 1997 | A |
5697915 | Lynn | Dec 1997 | A |
5698229 | Ohsumi | Dec 1997 | A |
5712229 | Hopkins | Jan 1998 | A |
5716406 | Farber | Feb 1998 | A |
5718678 | Fleming, III | Feb 1998 | A |
5738144 | Rogers | Apr 1998 | A |
5749861 | Guala | May 1998 | A |
5763412 | Khan | Jun 1998 | A |
5773487 | Sokol | Jun 1998 | A |
5806831 | Paradis | Sep 1998 | A |
5810768 | Lopez | Sep 1998 | A |
5817069 | Arnett | Oct 1998 | A |
5827239 | Dillon | Oct 1998 | A |
5830196 | Hicks | Nov 1998 | A |
5830401 | Prichard | Nov 1998 | A |
5833674 | Turnbull | Nov 1998 | A |
5843046 | Motisi | Dec 1998 | A |
5861440 | Gohla | Jan 1999 | A |
5911710 | Barry | Jun 1999 | A |
5944712 | Frassica | Aug 1999 | A |
5951519 | Utterberg | Sep 1999 | A |
5954698 | Pike | Sep 1999 | A |
5957898 | Jepson | Sep 1999 | A |
5967490 | Pike | Oct 1999 | A |
6039302 | Cote, Sr. | Mar 2000 | A |
6046143 | Khan | Apr 2000 | A |
6051609 | Yu | Apr 2000 | A |
6068622 | Sater | May 2000 | A |
6074379 | Prichard | Jun 2000 | A |
6077244 | Botich | Jun 2000 | A |
6102890 | Stivland | Aug 2000 | A |
6117108 | Woehr | Sep 2000 | A |
6120784 | Snyder, Jr. | Sep 2000 | A |
6127320 | Van Ooij | Oct 2000 | A |
6156054 | Zadno-Azizi | Dec 2000 | A |
6165168 | Russo | Dec 2000 | A |
6171287 | Lynn | Jan 2001 | B1 |
6217566 | Ju | Apr 2001 | B1 |
6228073 | Noone | May 2001 | B1 |
6242526 | Siddiqui | Jun 2001 | B1 |
6245098 | Feeser | Jun 2001 | B1 |
6248811 | Ottersbach | Jun 2001 | B1 |
6273404 | Holman | Aug 2001 | B1 |
6273869 | Vaillancourt | Aug 2001 | B1 |
6322847 | Zhong et al. | Nov 2001 | B1 |
6326417 | Jia | Dec 2001 | B1 |
6332874 | Eliasen | Dec 2001 | B1 |
6337357 | Fukunishi | Jan 2002 | B1 |
6344218 | Dodd | Feb 2002 | B1 |
6353041 | Qian | Mar 2002 | B1 |
6492445 | Siddiqui | Apr 2002 | B2 |
6387075 | Stivland | May 2002 | B1 |
6413539 | Shalaby | Jul 2002 | B1 |
6426373 | Stange | Jul 2002 | B1 |
6475434 | Darouiche | Nov 2002 | B1 |
6485473 | Lynn | Nov 2002 | B1 |
6488942 | Ingemann | Dec 2002 | B1 |
6503353 | Peterson | Jan 2003 | B1 |
6511462 | Itou | Jan 2003 | B1 |
6544214 | Utterberg | Apr 2003 | B1 |
6575958 | Happ | Jun 2003 | B1 |
6575960 | Becker | Jun 2003 | B2 |
6576633 | Young | Jun 2003 | B1 |
6579221 | Peterson | Jun 2003 | B1 |
6579539 | Lawson | Jun 2003 | B2 |
6595981 | Huet | Jul 2003 | B2 |
6663614 | Carter | Dec 2003 | B1 |
6699221 | Vaillancourt | Mar 2004 | B2 |
6719726 | Meng | Apr 2004 | B2 |
6719991 | Darouiche | Apr 2004 | B2 |
6723350 | Burrell | Apr 2004 | B2 |
6740063 | Lynn | May 2004 | B2 |
6808161 | Hishikawa | Oct 2004 | B1 |
6843784 | Modak | Jan 2005 | B2 |
6846846 | Modak | Jan 2005 | B2 |
6861060 | Luriya | Mar 2005 | B1 |
6883778 | Newton | Apr 2005 | B1 |
6887270 | Miller | May 2005 | B2 |
6893456 | Lumauig | May 2005 | B2 |
6896889 | Chevalier | May 2005 | B2 |
7008404 | Nakajima | Mar 2006 | B2 |
7074839 | Fansler | Jul 2006 | B2 |
7098256 | Ong | Aug 2006 | B2 |
7115183 | Larson | Oct 2006 | B2 |
7179849 | Terry | Feb 2007 | B2 |
7198800 | Ko | Apr 2007 | B1 |
7232428 | Inukai | Jun 2007 | B1 |
7232540 | Gould | Jun 2007 | B2 |
7261925 | Nesbitt | Aug 2007 | B2 |
7268165 | Greten | Sep 2007 | B2 |
7347839 | Hiejima | Mar 2008 | B2 |
7374798 | Choo | May 2008 | B2 |
7396346 | Nakajima | Jul 2008 | B2 |
7407707 | Gould | Aug 2008 | B2 |
7462401 | Halfyard | Dec 2008 | B2 |
7470254 | Basta | Dec 2008 | B2 |
7494339 | Dias | Feb 2009 | B2 |
7498367 | Qian | Mar 2009 | B2 |
7514477 | Klare | Apr 2009 | B2 |
7608082 | Cuevas | Oct 2009 | B2 |
7704935 | Davis | Apr 2010 | B1 |
7736339 | Woehr | Jun 2010 | B2 |
7816434 | Hackbarth | Oct 2010 | B2 |
7871649 | Modak | Jan 2011 | B2 |
7874467 | Pardes | Jan 2011 | B2 |
7914494 | Hiejima | Mar 2011 | B2 |
7981475 | Takahashi | Jul 2011 | B2 |
8034454 | Terry | Oct 2011 | B2 |
8034455 | Wang | Oct 2011 | B2 |
8067402 | Whiteford | Nov 2011 | B2 |
8133423 | Tang | Mar 2012 | B2 |
8227050 | O'Neil | Jul 2012 | B1 |
8231602 | Anderson | Jul 2012 | B2 |
8263102 | Labrecque | Sep 2012 | B2 |
8268381 | Whiteford | Sep 2012 | B2 |
8343523 | Toreki | Jan 2013 | B2 |
8343525 | Davis | Jan 2013 | B2 |
8353876 | Suwito | Jan 2013 | B2 |
8357119 | Stout | Jan 2013 | B2 |
8388583 | Stout | Mar 2013 | B2 |
8414547 | Difiore | Apr 2013 | B2 |
8512294 | Harding | Aug 2013 | B2 |
8574171 | Nesbitt | Nov 2013 | B2 |
8622995 | Ziebol | Jan 2014 | B2 |
8622996 | Ziebol | Jan 2014 | B2 |
8691887 | Ou-Yang | Apr 2014 | B2 |
8728030 | Woehr | May 2014 | B2 |
8840927 | Ditizio | Sep 2014 | B2 |
9078441 | Raad | Jul 2015 | B2 |
9138252 | Bierman | Sep 2015 | B2 |
20010010016 | Modak | Jul 2001 | A1 |
20010016589 | Modak | Aug 2001 | A1 |
20010018095 | Shlenker | Aug 2001 | A1 |
20010032006 | Griffin | Oct 2001 | A1 |
20010049519 | Holman | Dec 2001 | A1 |
20010053895 | Vaillancourt | Dec 2001 | A1 |
20010056133 | Montgomery | Dec 2001 | A1 |
20020009436 | Doyle | Jan 2002 | A1 |
20020022660 | Jampani | Feb 2002 | A1 |
20020028751 | Lokkesmoe | Mar 2002 | A1 |
20020037260 | Budny | Mar 2002 | A1 |
20020040092 | Siddiqui | Apr 2002 | A1 |
20020064858 | Yacoby-Zeevi | May 2002 | A1 |
20020091424 | Biel | Jul 2002 | A1 |
20020119111 | Kilgour | Aug 2002 | A1 |
20020133124 | Leinsing | Sep 2002 | A1 |
20020144705 | Brattesani | Oct 2002 | A1 |
20030023208 | Osypka | Jan 2003 | A1 |
20030060804 | Vaillancourt | Mar 2003 | A1 |
20030068667 | Olson | Apr 2003 | A1 |
20030072781 | Pelerin | Apr 2003 | A1 |
20030105143 | Ammendola | Jun 2003 | A1 |
20030119932 | Al-Akhdar | Jun 2003 | A1 |
20030134783 | Harshey | Jul 2003 | A1 |
20030144362 | Utterberg | Jul 2003 | A1 |
20030147932 | Nun | Aug 2003 | A1 |
20030162839 | Symington | Aug 2003 | A1 |
20030170308 | Cleary | Sep 2003 | A1 |
20030176848 | Gibson | Sep 2003 | A1 |
20030206875 | Budny | Nov 2003 | A1 |
20030215433 | Kokai-Kun | Nov 2003 | A1 |
20030224032 | Read | Dec 2003 | A1 |
20040013574 | Conway | Jan 2004 | A1 |
20040013703 | Ralph | Jan 2004 | A1 |
20040014864 | Milic | Jan 2004 | A1 |
20040039349 | Modak | Feb 2004 | A1 |
20040058829 | Hei | Mar 2004 | A1 |
20040062592 | Shekalim | Apr 2004 | A1 |
20040109852 | Xu | Jun 2004 | A1 |
20040115477 | Nesbitt | Jun 2004 | A1 |
20040132164 | Doyle | Jul 2004 | A1 |
20040180829 | Bassler | Sep 2004 | A1 |
20040185296 | Mazzanti | Sep 2004 | A1 |
20040230162 | Tan | Nov 2004 | A1 |
20040234475 | Lannibois-Drean | Nov 2004 | A1 |
20050008671 | Van Antwerp | Jan 2005 | A1 |
20050048005 | Stockel | Mar 2005 | A1 |
20050048124 | Sarangapani | Mar 2005 | A1 |
20050059731 | Albrecht | Mar 2005 | A1 |
20050080158 | Ong | Apr 2005 | A1 |
20050100580 | Osborne | May 2005 | A1 |
20050118239 | Sabesan | Jun 2005 | A1 |
20050124970 | Kunin | Jun 2005 | A1 |
20050131356 | Ash | Jun 2005 | A1 |
20050143286 | Singh | Jun 2005 | A1 |
20050147525 | Bousquet | Jul 2005 | A1 |
20050148928 | Molina | Jul 2005 | A1 |
20050158253 | Budny | Jul 2005 | A1 |
20050176905 | Moon | Aug 2005 | A1 |
20050209581 | Butts | Sep 2005 | A1 |
20050209583 | Powers | Sep 2005 | A1 |
20050233950 | Madhyastha | Oct 2005 | A1 |
20050265931 | Qian | Dec 2005 | A1 |
20060024372 | Utterberg | Feb 2006 | A1 |
20060051385 | Scholz | Mar 2006 | A1 |
20060064159 | Porter | Mar 2006 | A1 |
20060163515 | Ruschke | Jul 2006 | A1 |
20060165751 | Chudzik | Jul 2006 | A1 |
20060165903 | Mazzanti | Jul 2006 | A1 |
20060177477 | Ash | Aug 2006 | A1 |
20060239954 | Sancho | Oct 2006 | A1 |
20060258780 | Chaussade | Nov 2006 | A1 |
20060259012 | Propp | Nov 2006 | A1 |
20060281663 | Asmus | Dec 2006 | A1 |
20070000407 | Leong | Jan 2007 | A1 |
20070083157 | Belley | Apr 2007 | A1 |
20070083162 | O'Reagan | Apr 2007 | A1 |
20070093762 | Utterberg et al. | Apr 2007 | A1 |
20070112112 | Kerschner | May 2007 | A1 |
20070112146 | Falk | May 2007 | A1 |
20070129690 | Rosenblatt | Jun 2007 | A1 |
20070141524 | Brennan | Jun 2007 | A1 |
20070160547 | Duffy | Jul 2007 | A1 |
20070166344 | Qu | Jul 2007 | A1 |
20070202177 | Hoang | Aug 2007 | A1 |
20070203574 | McGrath | Aug 2007 | A1 |
20070225179 | Schutz | Sep 2007 | A1 |
20070233007 | Adams | Oct 2007 | A1 |
20070275101 | Lu | Nov 2007 | A1 |
20070281198 | Lousenberg | Dec 2007 | A1 |
20080026026 | Lu | Jan 2008 | A1 |
20080027410 | Harding | Jan 2008 | A1 |
20080033371 | Updegraff et al. | Feb 2008 | A1 |
20080039796 | Nakajima | Feb 2008 | A1 |
20080051737 | Paul | Feb 2008 | A1 |
20080075761 | Modak | Mar 2008 | A1 |
20080103487 | Miyasaka | May 2008 | A1 |
20080108944 | Woehr | May 2008 | A1 |
20080119789 | Kaemmerer | May 2008 | A1 |
20080161763 | Harding | Jul 2008 | A1 |
20080182921 | Suh | Jul 2008 | A1 |
20080194707 | Potter | Aug 2008 | A1 |
20080319387 | Amisar et al. | Dec 2008 | A1 |
20090012220 | Yamane | Jan 2009 | A1 |
20090036768 | Seehusen | Feb 2009 | A1 |
20090062766 | Howlett | Mar 2009 | A1 |
20090101152 | Burk | Apr 2009 | A1 |
20090110844 | Platzer | Apr 2009 | A1 |
20090114327 | Breunig | May 2009 | A1 |
20090117164 | Toreki | May 2009 | A1 |
20090125118 | Gong | May 2009 | A1 |
20090157007 | McKinnon | Jun 2009 | A1 |
20090162530 | Nesbitt | Jun 2009 | A1 |
20090176907 | Subramanian | Jul 2009 | A1 |
20090188559 | Nesbitt | Jul 2009 | A1 |
20090211909 | Nesbitt | Aug 2009 | A1 |
20090220739 | Chougule | Sep 2009 | A1 |
20090226541 | Scholz | Sep 2009 | A1 |
20090281525 | Harding | Nov 2009 | A1 |
20090299452 | Eidenschink | Dec 2009 | A1 |
20090317435 | Vandesteeg | Dec 2009 | A1 |
20090324666 | Krongauz | Dec 2009 | A1 |
20090324738 | Krongauz | Dec 2009 | A1 |
20100015200 | McClain | Jan 2010 | A1 |
20100024648 | Breault | Feb 2010 | A1 |
20100069854 | Okoh | Mar 2010 | A1 |
20100106102 | Ziebol | Apr 2010 | A1 |
20100106103 | Ziebol | Apr 2010 | A1 |
20100135949 | Ou-Yang | Jun 2010 | A1 |
20100136209 | Ou-Yang | Jun 2010 | A1 |
20100137379 | Ou-Yang | Jun 2010 | A1 |
20100137472 | Ou-Yang | Jun 2010 | A1 |
20100200017 | Kerr | Aug 2010 | A1 |
20100204648 | Stout | Aug 2010 | A1 |
20100204675 | Woehr | Aug 2010 | A1 |
20100222746 | Burkholz | Sep 2010 | A1 |
20110009831 | Burkholz | Jan 2011 | A1 |
20110044850 | Solomon et al. | Feb 2011 | A1 |
20110065798 | Hoang | Mar 2011 | A1 |
20110146680 | Conway | Jun 2011 | A1 |
20110150958 | Davis | Jun 2011 | A1 |
20110160662 | Stout | Jun 2011 | A1 |
20110160663 | Stout | Jun 2011 | A1 |
20110218529 | Garcia | Sep 2011 | A1 |
20110301553 | Goral | Dec 2011 | A1 |
20110319825 | Goral | Dec 2011 | A1 |
20120016318 | Hoang et al. | Jan 2012 | A1 |
20120078203 | Gaube | Mar 2012 | A1 |
20120083750 | Sansoucy | Apr 2012 | A1 |
20120103448 | Hopf | May 2012 | A1 |
20120111368 | Rahimy et al. | May 2012 | A1 |
20130090607 | McKinnon | Apr 2013 | A1 |
20130165868 | Isaacson | Jun 2013 | A1 |
20130171030 | Ferlic et al. | Jul 2013 | A1 |
20130196079 | Schwalm | Aug 2013 | A1 |
20130197485 | Gardner et al. | Aug 2013 | A1 |
20130204231 | Ziebol et al. | Aug 2013 | A1 |
20130245568 | Kerr | Sep 2013 | A1 |
20130274686 | Ziebol | Oct 2013 | A1 |
20130310764 | Burkholz | Nov 2013 | A1 |
20130330387 | Ou-yang | Dec 2013 | A1 |
20160008517 | Burkholz | Jan 2016 | A1 |
20170095596 | Petrak et al. | Apr 2017 | A1 |
Number | Date | Country |
---|---|---|
1331333 | Aug 1994 | CA |
2133053 | Mar 1995 | CA |
1187598 | Jul 1998 | CN |
1526771 | Sep 2004 | CN |
101353545 | Jan 2009 | CN |
102070983 | May 2011 | CN |
102481391 | May 2012 | CN |
102497894 | Jun 2012 | CN |
3314640 | Nov 1983 | DE |
3913392 | Oct 1990 | DE |
4011867 | Oct 1991 | DE |
202009009602 | Dec 2009 | DE |
0036294 | Sep 1981 | EP |
0070087 | Jan 1983 | EP |
0227230 | Jul 1987 | EP |
0328421 | Aug 1989 | EP |
0338418 | Oct 1989 | EP |
0370997 | May 1990 | EP |
0379271 | Jul 1990 | EP |
0396431 | Nov 1990 | EP |
0414997 | Mar 1991 | EP |
484092 | May 1992 | EP |
0778337 | Jun 1997 | EP |
0992252 | Apr 2000 | EP |
1466645 | Oct 2004 | EP |
1679043 | Jul 2006 | EP |
2868722 | May 2015 | EP |
05277434 | Oct 1993 | JP |
H07-051651 | Feb 1995 | JP |
H0747435 | Feb 1995 | JP |
08-182764 | Jul 1996 | JP |
H08209064 | Aug 1996 | JP |
H08311373 | Nov 1996 | JP |
09151262 | Jun 1997 | JP |
H09157548 | Jun 1997 | JP |
H09176677 | Jul 1997 | JP |
09-324135 | Dec 1997 | JP |
H10-000231 | Jan 1998 | JP |
H10-192415 | Jul 1998 | JP |
H11-507275 | Jun 1999 | JP |
H11322560 | Nov 1999 | JP |
2000178475 | Jun 2000 | JP |
2000264803 | Sep 2000 | JP |
2001072438 | Mar 2001 | JP |
2002510774 | Apr 2002 | JP |
2002282762 | Oct 2002 | JP |
2003342402 | Dec 2003 | JP |
2004043669 | Feb 2004 | JP |
2005028209 | Feb 2005 | JP |
2005512610 | May 2005 | JP |
2005515838 | Jun 2005 | JP |
2005520912 | Jul 2005 | JP |
2007016096 | Jan 2007 | JP |
2008533051 | Aug 2008 | JP |
2009-527356 | Jul 2009 | JP |
2009-528360 | Aug 2009 | JP |
2009-544454 | Dec 2009 | JP |
2010-174075 | Aug 2010 | JP |
2010536836 | Dec 2010 | JP |
2012-510559 | May 2012 | JP |
2012100762 | May 2012 | JP |
2012532681 | Dec 2012 | JP |
2013-505062 | Feb 2013 | JP |
2013533005 | Aug 2013 | JP |
2013540486 | Nov 2013 | JP |
2015-519303 | Jul 2015 | JP |
20020066429 | Aug 2002 | KR |
8200413 | Feb 1982 | WO |
9422522 | Oct 1994 | WO |
9521648 | Aug 1995 | WO |
9616690 | Jun 1996 | WO |
9640359 | Dec 1996 | WO |
9858690 | Dec 1998 | WO |
9858989 | Dec 1998 | WO |
9916498 | Apr 1999 | WO |
9932168 | Jul 1999 | WO |
9934849 | Jul 1999 | WO |
9936490 | Jul 1999 | WO |
9944654 | Sep 1999 | WO |
9943971 | Sep 1999 | WO |
0012171 | Mar 2000 | WO |
0066189 | Nov 2000 | WO |
0074743 | Dec 2000 | WO |
0147592 | Jul 2001 | WO |
0195862 | Dec 2001 | WO |
02051464 | Jul 2002 | WO |
2004071568 | Aug 2004 | WO |
2004108091 | Dec 2004 | WO |
2005037340 | Apr 2005 | WO |
2006012446 | Feb 2006 | WO |
2006056482 | Jun 2006 | WO |
2006074666 | Jul 2006 | WO |
2006088288 | Aug 2006 | WO |
2006099358 | Sep 2006 | WO |
2006099359 | Sep 2006 | WO |
2006100442 | Sep 2006 | WO |
2007052656 | May 2007 | WO |
2007064835 | Jun 2007 | WO |
2007095576 | Aug 2007 | WO |
2007100653 | Sep 2007 | WO |
2007100776 | Sep 2007 | WO |
2008014438 | Jan 2008 | WO |
2008014447 | Jan 2008 | WO |
2008031601 | Mar 2008 | WO |
2008045761 | Apr 2008 | WO |
20080039460 | Apr 2008 | WO |
2008052790 | May 2008 | WO |
2008128896 | Oct 2008 | WO |
2008132045 | Nov 2008 | WO |
2008152849 | Dec 2008 | WO |
2009012336 | Jan 2009 | WO |
2009055949 | May 2009 | WO |
2009070227 | Jun 2009 | WO |
2009114833 | Sep 2009 | WO |
2010034470 | Apr 2010 | WO |
2010093791 | Aug 2010 | WO |
2011005951 | Jan 2011 | WO |
2011034675 | Mar 2011 | WO |
2011048204 | Apr 2011 | WO |
WO-2011118680 | Sep 2011 | WO |
2012036916 | Mar 2012 | WO |
2013009998 | Jan 2013 | WO |
2013134421 | Sep 2013 | WO |
2013151860 | Oct 2013 | WO |
2014031774 | Feb 2014 | WO |
2015133281 | Sep 2015 | WO |
2015137098 | Sep 2015 | WO |
Entry |
---|
Anusavice KJ, Zhang N-Z, Shen C. Controlled Release of Chlorhexidine from UDMA-TEGDMA Resin, Journal of dental research, 2006;85(10); 950-954. |
Cabot Corporation, “Using Silicas and Aluminas in Coatins,” www.cabot-corp.com/Silicas-And-Aluminas/Coatings, downloaded from the internet on Apr. 26, 2011. |
ComfortCoat Hydrophilic Coating, DSM in Medical, http://www.dsm.com/en_US/medical/public/home/pages/product- coating-comfortcoat.jsp, Updated Jan. 11, 2013, Printed Apr. 22, 2013. |
Elson Silva, PhD, “Respecting Hydrology Science in the Patenting System,” pp. 1-7, Jan. 13, 2011. |
Enluria, ChloraPrep, http://enluria.com/products/cloraPrep-product.html, pp. 1-3, Oct. 21, 2008. |
Gama Healthcare, Clinell Alcoholic 2% Chlorhexidine, http//www.gamahealthcare.com/clinellaca2c.html, pp. 1-3, Nov. 7, 2008. |
Gerald McDonnell and A. Denver Russell, Antiseptics and Disinfectants: Activity, Action and Resistance, Clinical Microbiology Reviews, vol. 12, Jan. 1999, p. 147-179. |
Lubricent—Lubricious Hydrophillic Coatings for Medical Devices, Harland Medical Systems, http://www. harlandmedical.com/index.php/materials/lubricent.html, pp. 1-2, Printed Apr. 22, 2013. |
Sage Products, Inc., Address Multi-Drug Reistant Organism on the Skin with Early Preop Prep, http://www.sageproducts.com/products/ssi-prevention.cfm, 1 page, Oct. 31, 2008. |
Ciba Irgacure 500 data sheet from Ciba Specialty Chamicals, online, retrieved on [Dec. 13, 2015]. Retrieved from internet URL <http://www.conquimica.com/wp-content/uploads/2015/06/ft_igracure_500.pdf>. |
Sage Products, Inc., Preoperative Skin Preparation and Preoperative Oral Care for the Short-Term Ventilated Patient, http://www.sageproducts.com/products/ssi-vap-prevention.cfm. |
Sage Products, Inc., Preoperative Skin Preparation for the Surgical Patient, http://www.sageproducts.com/products/skin-prep.cfm, 1 page, Oct. 31, 2008. |
UV & EB Cure, Xiper Innovations, Inc., http://xiperinnovations.com/uv_eb_cure, Printed Apr. 22, 2013. |
Number | Date | Country | |
---|---|---|---|
20180021543 A1 | Jan 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14260071 | Apr 2014 | US |
Child | 15709221 | US |